Is AstraZeneca angling for a blockbuster Amarin buyout?

New Amarin ($AMRN) buyout gossip: The U.K. newspaper The Daily Mail has reported speculation that Pascal Soriot, AstraZeneca's ($AZN) new chief executive, has set his sights on a purchase of Ireland-based Amarin and the biotech company's newly approved Vascepa, a prescription strength fish oil for combatting blood fats that could become a blockbuster seller. As the rumor mill about the potential acquisition of Amarin turns, the company's stock price jumped more than 6% as of 11:50 a.m. ET today. Of course, such speculation often amounts to nothing, but Amarin CEO Joseph Zakrzewski has voiced his openness to a sale of the company and Soriot recently hit the brakes on a multibillion-dollar share buyback plan at Astra in a move widely seen as setting the stage for M&A activity. Article

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.